FY2029 EPS Estimates for Pyxis Oncology Increased by Analyst

Posted by George Bondi on May 20th, 2026

Pyxis Oncology, Inc. (NASDAQ:PYXS – Free Report) – Investment analysts at HC Wainwright upped their FY2029 EPS estimates for Pyxis Oncology in a note issued to investors on Friday, May 15th. HC Wainwright analyst S. Ramakanth now expects that the company will earn $0.30 per share for the year, up from their prior forecast of $0.27. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Pyxis Oncology’s FY2030 earnings at $0.99 EPS.

A number of other equities research analysts have also recently commented on PYXS. Stifel Nicolaus reduced their target price on shares of Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, March 24th. Wall Street Zen cut shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. Finally, Wedbush assumed coverage on shares of Pyxis Oncology in a research report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price objective for the company. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Pyxis Oncology has an average rating of “Moderate Buy” and an average target price of $6.83.

Get Our Latest Stock Analysis on Pyxis Oncology

Pyxis Oncology Stock Down 5.4%

Shares of NASDAQ PYXS opened at $1.91 on Monday. The firm has a 50-day simple moving average of $1.74 and a 200-day simple moving average of $2.27. The stock has a market capitalization of $121.00 million, a price-to-earnings ratio of -1.46 and a beta of 1.43. Pyxis Oncology has a 52 week low of $0.97 and a 52 week high of $5.55.

Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last issued its earnings results on Thursday, May 14th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02).

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Laurion Capital Management LP boosted its stake in Pyxis Oncology by 32.3% during the fourth quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock worth $5,516,000 after buying an additional 1,170,505 shares during the period. Vanguard Group Inc. boosted its stake in Pyxis Oncology by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock worth $4,804,000 after buying an additional 14,566 shares during the period. 683 Capital Management LLC boosted its stake in Pyxis Oncology by 69.9% during the fourth quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock worth $1,026,000 after buying an additional 366,910 shares during the period. Renaissance Technologies LLC boosted its stake in Pyxis Oncology by 22.0% during the first quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock worth $1,297,000 after buying an additional 160,300 shares during the period. Finally, Jane Street Group LLC boosted its stake in Pyxis Oncology by 158.8% during the fourth quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock worth $904,000 after buying an additional 482,310 shares during the period. Hedge funds and other institutional investors own 39.07% of the company’s stock.

Pyxis Oncology News Roundup

Here are the key news stories impacting Pyxis Oncology this week:

Positive Sentiment: HC Wainwright kept a Buy rating on Pyxis Oncology and a $7.00 price target, signaling continued confidence in the company’s longer-term upside despite near-term losses. Article Title
Positive Sentiment: HC Wainwright raised its FY2027 EPS estimate for Pyxis Oncology, which may indicate improving expectations further out. Article Title
Positive Sentiment: Guggenheim also reportedly initiated or reiterated a Buy view on PYXS, adding another supportive analyst call. Article Title
Neutral Sentiment: The latest coverage is centered on earnings estimate revisions, with analysts adjusting projections across 2026-2028 rather than reporting a new clinical or commercial catalyst.
Negative Sentiment: HC Wainwright cut Q2 2026 EPS estimates to ($0.38) from ($0.36), pointing to slightly weaker near-term profitability expectations.
Negative Sentiment: The firm also lowered FY2026 EPS to ($0.99) from ($0.95) and reduced FY2028 EPS to ($0.35), which may weigh on sentiment around the stock’s path to earnings improvement.
Negative Sentiment: HC Wainwright also trimmed its Q3 2026 EPS estimate, reinforcing pressure on the near-term outlook.

Pyxis Oncology Company Profile

(Get Free Report)

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.